Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221716 | 0.81 | ATM (0.41) | ATMALDH1A1L3MBTL1LMNACYP2C19 | |
| SCHEMBL25554214 | 0.80 | ATM (0.47) | ATMCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25544491 | 0.80 | ATM (0.47) | ATMCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25544492 | 0.80 | ATM (0.47) | ATMCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13896056 | 0.77 | ATM (0.45) | ATMCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19715998 | 0.77 | ATM (0.49) | ATMCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16821979 | 0.77 | ATM (0.45) | ATMCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Formic Acid SCHEMBL27859384 | 0.75 | ATM (0.38) | ATML3MBTL1CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL9756136 | 0.75 | CD81 (0.33) | LMNACYP2C19CYP1A2CYP2C9KMT2A | |
| SCHEMBL12496346 | 0.75 | APLNR (0.37) | ATMALDH1A1LMNACYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ATM 3899/4885ALDH1A1 1584/4885CHRNB2 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.